Allergy Asthma Immunol Res:鼻一氧化氮与鼻腔通畅和鼻症状有关

2019-04-16 AlexYang MedSci原创

一氧化氮(NO)在上呼吸道和下呼吸道系统中是一种重要的内源性调节因子。最近,有研究人员阐释了中国成年人的鼻NO(nNO)正常范围以及内在的影响因子,并且进一步调查了鼻炎和无症状特应性人群之间的nNO水平差异以及过敏性鼻炎(AR)中诊断nNO的价值。研究包括了1000名成年人,并根据调查问卷和皮刺试验分成不同的亚群。研究发现,nNO和FeNO水平在AR患者中要比健康和无症状特应性参与者显著更高。nN

一氧化氮(NO)在上呼吸道和下呼吸道系统中是一种重要的内源性调节因子。最近,有研究人员阐释了中国成年人的鼻NO(nNO)正常范围以及内在的影响因子,并且进一步调查了鼻炎和无症状特应性人群之间的nNO水平差异以及过敏性鼻炎(AR)中诊断nNO的价值。

研究包括了1000名成年人,并根据调查问卷和皮刺试验分成不同的亚群。研究发现,nNO和FeNO水平在AR患者中要比健康和无症状特应性参与者显著更高。nNO水平在无症状特应性受试者中要比正常成年人显著更低。FeNO水平在非AR患者中要比健康和无症状特应性成年人中显著更高。AR诊断的nNO截断值为117.5ppb(敏感度,50.9%;特异性,63.9%)。另外,nNO水平与FeNO水平,75Pa时的总鼻阻力,距前鼻孔0-7厘米鼻容积和鼻症状视觉模拟量表(VAS)评分相关,而FeNO水平与年龄、身高、体重、身体表面积距前鼻孔0-7厘米鼻容积和鼻症状VAS评分相关。

最后,研究人员指出,nNO水平在健康和AR患者之间显著不同,并且可能与鼻炎患者的鼻症状和鼻通畅明显相关。然而,nNO的临床价值仍处在探索阶段。

原始出处:

Ren L, Zhang W, Zhang Y et al. Nasal Nitric Oxide Is Correlated With Nasal Patency and Nasal Symptoms. Allergy Asthma Immunol Res. May 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1711917, encodeId=1c791e119174c, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Jun 01 04:09:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045977, encodeId=d6f920459e7d9, content=<a href='/topic/show?id=3c5710348311' target=_blank style='color:#2F92EE;'>#鼻症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103483, encryptionId=3c5710348311, topicName=鼻症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Mar 11 11:09:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977140, encodeId=407519e7140f3, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Aug 31 04:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329231, encodeId=31e5132923180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337381, encodeId=3b75133e38108, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465848, encodeId=2485146584807, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1711917, encodeId=1c791e119174c, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Jun 01 04:09:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045977, encodeId=d6f920459e7d9, content=<a href='/topic/show?id=3c5710348311' target=_blank style='color:#2F92EE;'>#鼻症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103483, encryptionId=3c5710348311, topicName=鼻症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Mar 11 11:09:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977140, encodeId=407519e7140f3, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Aug 31 04:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329231, encodeId=31e5132923180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337381, encodeId=3b75133e38108, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465848, encodeId=2485146584807, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1711917, encodeId=1c791e119174c, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Jun 01 04:09:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045977, encodeId=d6f920459e7d9, content=<a href='/topic/show?id=3c5710348311' target=_blank style='color:#2F92EE;'>#鼻症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103483, encryptionId=3c5710348311, topicName=鼻症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Mar 11 11:09:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977140, encodeId=407519e7140f3, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Aug 31 04:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329231, encodeId=31e5132923180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337381, encodeId=3b75133e38108, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465848, encodeId=2485146584807, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-08-31 skhzy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1711917, encodeId=1c791e119174c, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Jun 01 04:09:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045977, encodeId=d6f920459e7d9, content=<a href='/topic/show?id=3c5710348311' target=_blank style='color:#2F92EE;'>#鼻症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103483, encryptionId=3c5710348311, topicName=鼻症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Mar 11 11:09:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977140, encodeId=407519e7140f3, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Aug 31 04:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329231, encodeId=31e5132923180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337381, encodeId=3b75133e38108, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465848, encodeId=2485146584807, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-04-18 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1711917, encodeId=1c791e119174c, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Jun 01 04:09:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045977, encodeId=d6f920459e7d9, content=<a href='/topic/show?id=3c5710348311' target=_blank style='color:#2F92EE;'>#鼻症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103483, encryptionId=3c5710348311, topicName=鼻症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Mar 11 11:09:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977140, encodeId=407519e7140f3, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Aug 31 04:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329231, encodeId=31e5132923180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337381, encodeId=3b75133e38108, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465848, encodeId=2485146584807, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1711917, encodeId=1c791e119174c, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Jun 01 04:09:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045977, encodeId=d6f920459e7d9, content=<a href='/topic/show?id=3c5710348311' target=_blank style='color:#2F92EE;'>#鼻症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103483, encryptionId=3c5710348311, topicName=鼻症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Mar 11 11:09:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977140, encodeId=407519e7140f3, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Aug 31 04:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329231, encodeId=31e5132923180, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337381, encodeId=3b75133e38108, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465848, encodeId=2485146584807, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Apr 18 04:09:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-04-18 mnda

相关资讯

Adv Mater:报道华东理工一氧化氮抗肿瘤纳米药物研究新进展

李永生教授团队在一氧化氮(NO)抗肿瘤纳米药物领域研究取得新进展,相关工作成果以“Dual intratumoral redox/enzyme-responsive NO-releasing nanomedicine for the specific, high-efficacy and low-toxic cancer therapy”为题,在线发表于Advanced Materials上。

Stem cells:骨髓间充质干细胞分泌的微泡可提高造血干细胞的移植效率

白血病、淋巴瘤、重度再生障碍性贫血等患者常采用骨髓移植,骨髓移植的成功与否关键在于移植的造血细胞(HSCs)的有效植入。当供体HSCs的数量和质量是限制因素时,通过体外对HSCs的操作来提高植入性就成了必要。鉴于骨髓间充质干细胞(MSCs)具有造血支持作用,其往常被用作HSCs体外扩增的滋养层。MSCs在体内可形成特异性HSC壁龛,表明MSCs内存在可影响HSC命运的信号机制。Sapana Jal

Auris Nasus Larynx:在过敏性鼻炎中,鼻用皮质类固醇治疗能够减少下鼻甲表面的一氧化氮水平

是否鼻一氧化氮(NO)可以作为评估过敏性鼻炎(AR)患者治疗效果的一个可靠参数仍旧具有争议。在有症状的AR患者诊断中,局部NO水平的测量表明NO是一个敏感的标记。最近,有研究人员评估了鼻NO在评估鼻用皮质类固醇(INS)治疗效果中的应用情况。研究包括了25名患有永久性AR和10名年龄匹配的健康参与者。研究发现,糠酸氟替卡松(FF)治疗后,AR患者的总鼻症状得分显著减少。在治疗前,AR患者中下鼻甲(

CLIN CANCER RES:MDSC产生的一氧化氮损伤FcR介导的NK细胞功能

单克隆抗体常用于治疗实体和血液学肿瘤,部分通过NK细胞的Fc受体(FcR)起作用。但是,肿瘤患者FcR介导的NK细胞功能显着受损。明确这一功能紊乱及抗体治疗反应受损机制有助于发展联合疗法增强抗体治疗效果。CLIN CANCER RES近期发表了一篇文章研究这一问题。

PLoS Biol:阐明神经元细胞的沟通机制 有望开发出治疗多种神经变性疾病的新型疗法

近日,一项刊登在国际杂志PLOS Biology上的研究报告中,来自莱斯特大学的研究人员通过研究阐明了大脑中的神经元细胞之间彼此进行沟通的分子机制,相关研究或能帮助研究人员理解多种神经变性疾病发生的分子机制。

Nature Chemical Biology:新型NO靶向递送系统 为治疗血管损伤提供新策略

一氧化氮(NO)是心血管系统的一个重要气体信号分子,在维持血管正常生理功能中发挥重要作用,并对血管稳态进行精密调控。人们所熟知的经典心血管药物——硝酸甘油,就是通过释放一氧化氮发挥扩张血管作用的。但是,过高剂量的NO会导致细胞凋亡,产生毒性。如果NO全身性释放还会导致血压下降、心跳加速等副作用。因此,发展精准的NO递送系统,实现靶向传输是目前该领域研究热点,也是制约NO生物材料临床应用的“瓶颈”。